A study showed that about 45% of dementias are preventable through lifestyle modifications. The societal impacts of this research include reducing financial burdens on the health care system, improving social participation and population health, and improving quality of life for millions of Americans. “Primary care clinicians can now start the conversation about cognitive health with…
New monoclonal antibody therapies targeting beta-amyloid deposition in the brain have shown success in slowing the progression of Alzheimer’s disease, though the risk of serious side effects necessitates careful evaluation and discussion before initiating treatment.. In January 2023, the Food and Drug Administration (FDA) gave accelerated approval to lecanemab, which goes by the brand name…
Neuromuscular disorders are conditions that affect the structure and function of the peripheral nervous system, as well as all motor and sensory nerves. The predominant symptom of this group of disorders is progressive muscle weakness. Secondary symptoms may include muscular atrophy and disturbances in sensation, which may present as tingling or numbness. The developments in…
Physician assistant Kendall M. Wasz, PA-C, has joined the memory care team at Norton Neuroscience Institute. Kendall holds Master of Science degree in physician assistant studies from the University of Kentucky, Lexington, and earned her bachelor’s degree at Miami University, Oxford, Ohio. Kendall brings a deeply personal and compassionate approach to the field of dementia…
Norton Research Institute will expand research efforts with the unveiling of the new Norton Research Institute Clinical & Translational Research Laboratory. The 7,200-square-foot facility, located inside Norton Healthcare Pavilion in downtown Louisville, will afford ample space and resources for scientists to conduct cutting-edge research, with the goal of producing more meaningful, applicable results directly benefiting patient…
In 2023, the Food and Drug Administration (FDA) approved lecanemab (brand name Leqembi) for the treatment of Alzheimer’s disease. Lecanemab is the first widely used medication in a new class of anti-amyloid agents for the treatment of patients with mild cognitive impairment (MCI) or early stages of Alzheimer’s disease. This is the first new Alzheimer’s…
Christopher P. Rhyne, M.D., is a headache medicine specialist at Norton Neuroscience Institute. He earned his medical degree from Windsor University School of Medicine, St. Kitts, West Indies. He completed his residency in family medicine at the University of Illinois Chicago. Dr. Rhyne comes to Norton Neuroscience Institute Headache Center from the Diamond Headache Clinic…
The initial evaluation for trigeminal neuralgia is typically in primary care, but patients frequently also present to dental and ear, nose and throat settings, according to Brian M. Plato, D.O., a neurologist and headache specialist with Norton Neuroscience Institute. The uncommon condition is characterized by facial pain within the distribution of the trigeminal nerve. Abigail…
After completing a pair of spinal fellowships in the latest surgical techniques and technologies, Shawn W. Adams, M.D., has joined Norton Leatherman Spine and Norton Neuroscience Institute. Dr. Adams’ fellowships covered complex adult spine, deformity and minimally invasive techniques. “I try to develop a relationship with my patients and partner with them to get the…
Butyrate-producing gut bacteria are a promising target for preventing and treating memory loss associated with Alzheimer’s disease, according to research presented recently at the Alzheimer’s Association International Conference (AAIC) in Amsterdam, Netherlands. The research in 3XTg mouse model demonstrated that oral administration of tributyrin mitigates age-associated loss of butyrate-producing bacteria and prevents the decline in…
Early treatment for patients with multiple sclerosis (MS) reduces the number and severity of flare-ups, delays disease progression and is associated with decreased long-term disability from neurological deficits compared with MS patients who did not begin treatment early. “Getting and staying on disease-modifying therapy is important, even when no symptoms are present, because the disease…
The patient A 67-year-old woman presented to clinic with a four-year history of right-sided facial pain. After the onset of her trouble, the pain went into remission for six months. It then recurred, and she was prescribed carbamazepine. This led to significant pain relief but caused adverse changes to her mood and balance. She was…